Hybrigenics SA Brings its Fee-for-service Activities to Hybrigenics Services SAS
Want to listen to this article for FREE?
Complete the form below to unlock access to ALL audio articles.
Read time: 1 minute
Hybrigenics SA, a bio-pharmaceutical company with a focus on research and development of new cancer treatments and specialized in protein interactions, has announced that its fee-for-service scientific activities are brought to a fully-owned subsidiary named Hybrigenics Services SAS.
Hybrigenics Services SAS will focus on further growth of fee-for-service businesses.
The Annual General Meeting on June 25, 2010 approved the creation of a subsidiary called Hybrigenics Services SAS, fully-owned by Hybrigenics SA. This business generated EUR 3.27 million revenue in 2009 (up 8 percent from the prior year) and operates independently within Hybrigenics SA.
Hybrigenics Services SAS will enjoy greater independence as a separate profit center, especially in terms of access to working capital to finance an aggressive marketing and sales strategy and to fuel organic and/or potential external growth.
Hybrigenics SA will remain focused on proprietary pharmaceutical R&D.
The Phase IIa clinical development study of inecalcitol produced very promising results in terms of tolerance and presumption of efficacy in hormone-refractory prostate cancer. The maximum tolerated oral dose of inecalcitol is extremely high: 4 milligram per day. The response rate to the combination treatment with Taxotere has now reached 84 percent: 38 patients out of 45 evaluable patients on prostate specific antigen (PSA) decline within 3 months. Patient enrolment has been completed up to 54 patients; the last treatments will take place in September. Given this excellent tolerance, Hybrigenics SA is considering testing oral inecalcitol in other potential indications, such as severe psoriasis.
Hybrigenics SA research on inhibitors of ubiquitin-specific proteases is at the forefront of innovation in the field of novel anticancer agents acting on the ubiquitin-proteasome system. Selective inhibitors of USP7 have been identified and protected by several patent applications. Their chemical optimization is ongoing.
Hybrigenics Services SAS will focus on further growth of fee-for-service businesses.
The Annual General Meeting on June 25, 2010 approved the creation of a subsidiary called Hybrigenics Services SAS, fully-owned by Hybrigenics SA. This business generated EUR 3.27 million revenue in 2009 (up 8 percent from the prior year) and operates independently within Hybrigenics SA.
Hybrigenics Services SAS will enjoy greater independence as a separate profit center, especially in terms of access to working capital to finance an aggressive marketing and sales strategy and to fuel organic and/or potential external growth.
Hybrigenics SA will remain focused on proprietary pharmaceutical R&D.
The Phase IIa clinical development study of inecalcitol produced very promising results in terms of tolerance and presumption of efficacy in hormone-refractory prostate cancer. The maximum tolerated oral dose of inecalcitol is extremely high: 4 milligram per day. The response rate to the combination treatment with Taxotere has now reached 84 percent: 38 patients out of 45 evaluable patients on prostate specific antigen (PSA) decline within 3 months. Patient enrolment has been completed up to 54 patients; the last treatments will take place in September. Given this excellent tolerance, Hybrigenics SA is considering testing oral inecalcitol in other potential indications, such as severe psoriasis.
Hybrigenics SA research on inhibitors of ubiquitin-specific proteases is at the forefront of innovation in the field of novel anticancer agents acting on the ubiquitin-proteasome system. Selective inhibitors of USP7 have been identified and protected by several patent applications. Their chemical optimization is ongoing.
